(Q37790600)

23 August 2017

The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review (English)

1 reference

23 August 2017

1 reference

1 reference

K A Burke

1

1 reference

23 August 2017

S N Freeman

series ordinal

2

1 reference

23 August 2017

M A Imoisili

series ordinal

3

1 reference

23 August 2017

T R Coté

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Clinical Pharmacology & Therapeutics

23 August 2017

1 reference

23 August 2017

88

1 reference

23 August 2017

4

1 reference

23 August 2017

449-453

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2010.193

23 August 2017

0 references

cites work

The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.193

Crossref

reference URL

Incentives for orphan drug research and development in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.193

Crossref

reference URL

Stem cells in human neurodegenerative disorders--time for clinical translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.193

Crossref

reference URL

21 January 2018

Identifiers

DOI

10.1038/CLPT.2010.193

1 reference

Dimensions Publication ID

23 August 2017

0 references

1 reference